Survival and proliferation of prostate cancer cells depend critically on signaling through the androgen receptor (AR) and, consequently, standard therapies against prostate cancer involve androgen reduction through chemical or surgical castration [2, 3]. This evidence concerns the gene AR and prostate carcinoma.